Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques (SAKOS)
Primary Purpose
Spinal Fractures, Vertebral Compression Fractures, Back Injuries
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Vertebral fracture surgery SpineJack®
Balloon Kyphoplasty
Sponsored by
About this trial
This is an interventional treatment trial for Spinal Fractures
Eligibility Criteria
Inclusion Criteria:
- Male or Female with at least 50 years of age
1 painful VCF which at least meet all following criteria:
- Fracture due to diagnosed or presumed underlying osteoporosis
- VCF between T7 and L3
- Fracture age <3 months
- VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline
- The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI)
- Patient has failed conservative medical therapy, defined as either having a VAS back pain score of ≥50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥70mm at 2 weeks after initiation of fracture care
- Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op
- Patient has an Oswestry Disability Index (ODI) score of ≥ 30/100
- Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures
- The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments.
Exclusion Criteria:
- Target VCF due to underlying or suspected tumor
- Target VCF due to high-energy trauma
- Target VCF is diagnosed as an osteonecrotic fracture
- Segmental kyphosis of target VB of >30°
- Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level
- The patient has uncontrolled diabetes
- Pre-existing or clinically unstable neurologic deficit
- The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
- Any physical exam evidence of myelopathy or radiculopathy
- The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
- Patient not able to walk without assistance prior to fracture
- Any radiographic evidence of pedicle fracture visible on CT scan pre op
- Spondylolisthesis >Grade 1 at target VB
- Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
- A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
- Pain due to any other condition that requires daily narcotic medication
- Disabling back pain due to causes other than acute fracture
- History of intolerance or allergic reaction to titanium or acrylic compounds
- Active systemic or local infection at baseline
- Body mass index >40
- Severe cardiopulmonary deficiencies
- Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
- Any evidence of alcohol or drug abuse
- The patient has uncontrolled psychiatric illness or severe dementia
- The patient is currently on anti-cancer therapy or anti-HIV therapy
- Patient's life expectancy is less than the study duration or undergoing palliative care
- Participating in any other investigational study
- The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
- The patient is known to be involved in medical litigation including Workmen's Compensation
- Patient with contraindication for MRI
- The patient is pregnant or considering getting pregnant during study participation.
Sites / Locations
- Hôpital Jean Minjoz Service Neurochirurgie
- Centre Hospitalier La Cavale Blanche
- CHU La Timone
- Hôpital Nord
- CHU Hôtel Dieu Service Neuro traumatologie
- Klinik und Poliklinik fur Orthopädie Universitatsklinikum
- Loretto-Krankenhaus Freiburg
- Krankenhaus NEUWERK Sankt Augustinus kliniken
- Ospedale SS Trinita ASL8
- Hospital Universitario Marques de Valdecilla
- Hospital Clinico Universitario de Valladolid,
- HFR Fribourg - Hôpital cantonal
- Clinique Bois-Cerf
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
SpineJack® system
Balloon Kyphoplasty
Arm Description
VCF treatment system Vertebral fracture surgery
VCF treatment system Vertebral fracture surgery
Outcomes
Primary Outcome Measures
Proportion of Participants With Study Success
The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness):
Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND,
Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND,
Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.
Secondary Outcome Measures
Full Information
NCT ID
NCT02461810
First Posted
May 27, 2015
Last Updated
February 21, 2019
Sponsor
Vexim SA
Collaborators
ACES Ing.-GmbH
1. Study Identification
Unique Protocol Identification Number
NCT02461810
Brief Title
Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques
Acronym
SAKOS
Official Title
A Prospective, Multicenter, Randomized, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
February 20, 2018 (Actual)
Study Completion Date
February 20, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vexim SA
Collaborators
ACES Ing.-GmbH
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the safety and effectiveness of the SpineJack® with the Kyphx Xpander® Inflatable Bone Tamp and support a non-inferiority finding for the use of SpineJack® VCF treatment system versus Balloon Kyphoplasty.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Fractures, Vertebral Compression Fractures, Back Injuries, Osteoporosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
152 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SpineJack® system
Arm Type
Experimental
Arm Description
VCF treatment system Vertebral fracture surgery
Arm Title
Balloon Kyphoplasty
Arm Type
Active Comparator
Arm Description
VCF treatment system Vertebral fracture surgery
Intervention Type
Device
Intervention Name(s)
Vertebral fracture surgery SpineJack®
Intervention Description
Vertebral augmentation for one osteoporotic vertebral compression fracture
Intervention Type
Procedure
Intervention Name(s)
Balloon Kyphoplasty
Primary Outcome Measure Information:
Title
Proportion of Participants With Study Success
Description
The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness):
Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND,
Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND,
Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.
Time Frame
12 month post-op
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or Female with at least 50 years of age
1 painful VCF which at least meet all following criteria:
Fracture due to diagnosed or presumed underlying osteoporosis
VCF between T7 and L3
Fracture age <3 months
VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline
The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI)
Patient has failed conservative medical therapy, defined as either having a VAS back pain score of ≥50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥70mm at 2 weeks after initiation of fracture care
Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op
Patient has an Oswestry Disability Index (ODI) score of ≥ 30/100
Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures
The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments.
Exclusion Criteria:
Target VCF due to underlying or suspected tumor
Target VCF due to high-energy trauma
Target VCF is diagnosed as an osteonecrotic fracture
Segmental kyphosis of target VB of >30°
Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level
The patient has uncontrolled diabetes
Pre-existing or clinically unstable neurologic deficit
The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
Any physical exam evidence of myelopathy or radiculopathy
The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
Patient not able to walk without assistance prior to fracture
Any radiographic evidence of pedicle fracture visible on CT scan pre op
Spondylolisthesis >Grade 1 at target VB
Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
Pain due to any other condition that requires daily narcotic medication
Disabling back pain due to causes other than acute fracture
History of intolerance or allergic reaction to titanium or acrylic compounds
Active systemic or local infection at baseline
Body mass index >40
Severe cardiopulmonary deficiencies
Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
Any evidence of alcohol or drug abuse
The patient has uncontrolled psychiatric illness or severe dementia
The patient is currently on anti-cancer therapy or anti-HIV therapy
Patient's life expectancy is less than the study duration or undergoing palliative care
Participating in any other investigational study
The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
The patient is known to be involved in medical litigation including Workmen's Compensation
Patient with contraindication for MRI
The patient is pregnant or considering getting pregnant during study participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre HONTAS, Director Clinical Affairs
Organizational Affiliation
Vexim SA
Official's Role
Study Director
Facility Information:
Facility Name
Hôpital Jean Minjoz Service Neurochirurgie
City
Besancon
Country
France
Facility Name
Centre Hospitalier La Cavale Blanche
City
Brest
Country
France
Facility Name
CHU La Timone
City
Marseille
Country
France
Facility Name
Hôpital Nord
City
Marseille
Country
France
Facility Name
CHU Hôtel Dieu Service Neuro traumatologie
City
Nantes
Country
France
Facility Name
Klinik und Poliklinik fur Orthopädie Universitatsklinikum
City
Bonn
Country
Germany
Facility Name
Loretto-Krankenhaus Freiburg
City
Freiburg
Country
Germany
Facility Name
Krankenhaus NEUWERK Sankt Augustinus kliniken
City
Monchengladbach
Country
Germany
Facility Name
Ospedale SS Trinita ASL8
City
Cagliari
Country
Italy
Facility Name
Hospital Universitario Marques de Valdecilla
City
Santander
Country
Spain
Facility Name
Hospital Clinico Universitario de Valladolid,
City
Valladolid
Country
Spain
Facility Name
HFR Fribourg - Hôpital cantonal
City
Fribourg
Country
Switzerland
Facility Name
Clinique Bois-Cerf
City
Lausanne
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques
We'll reach out to this number within 24 hrs